Cargando cotizaciones...
Previsión
| Comprar |
0 |
| Mantener |
1 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Ontex reports sales decline in 2025 and targets 10% EBITDA growth for 2026
Ontex recorded a sales decline in 2025 to €1,762m and an adjusted EBITDA of €176m (margin 10.0% vs. 12.0% in 2024), driven by weak baby-care demand, higher raw material costs and operational disruptions. The company posted an overall loss of €174m, which included a €190m loss from discontinued operations, and generated a negative free cash flow of -€25m. Net debt fell to €577m, but the leverage ratio rose to 3.3x. For 2026 Ontex expects broadly stable sales, a 10% increase in adjusted EBITDA, a return to positive free cash flow and a reduction of leverage to around 3.0 or below; measures include cost transformation, efficiency improvements and a strategic review. » Más en de.investing.com
Ontex accelerates CEO change and launches comprehensive strategy review
Ontex has brought forward the leadership change: Laurent Nielly assumes the role of CEO with immediate effect, while Gustavo Paz will remain until the end of January to facilitate the handover. The company announced a full strategic review of its portfolio, operational setup and distribution channels and has established a strategy committee of the board. The measures are aimed at higher cash generation and improved returns; the announcement sent the share price markedly higher. » Más en de.investing.com
S&P cuts outlook for Ontex to stable after second profit warning
S&P Global Ratings has downgraded the outlook for Ontex from “positive” to “stable”; the B+ rating remains unchanged. The move follows a second profit warning for 2025 with a lowered sales forecast (core markets: −4 to −6 %) and adjusted EBITDA of €175–180m. S&P expects a reported sales decline of around 14% in 2025, an EBITDA margin of about 7.5% and no positive free operating cash flow. For 2026 S&P anticipates a moderate recovery (sales ~€1.79–1.80bn, adjusted EBITDA margin towards 10% and FOCF around €30m); Ontex also plans a €200m cost-efficiency program for 2026–2028. » Más en de.investing.com
Ontex warns of weaker 2025 performance and stock drops sharply
Ontex's shares fell about 18% after a profit warning for 2025 and the announcement of a CEO succession. The company now expects a mid-single-digit decline in like-for-like sales and has revised adjusted EBITDA to €175–180m (previously €200–210m), well below the analyst consensus. Reasons are weaker consumer demand in the European baby care business and lower volumes from new contracts; free cash flow is expected to show an outflow of €35m in 2025 and net debt is forecast to rise to 3.2x EBITDA. Ontex plans an efficiency programme targeting €200m in savings over three years; Laurent Nielly will succeed Gustavo Calvo Paz as CEO on 5 May 2026. » Más en de.investing.com
Ontex reports Q3 2025: sales fall year-on-year, sequential recovery visible
Ontex reported Q3 2025 sales of €445 million (-3.8% like‑for‑like year‑on‑year) with a sequential improvement of 3.7% versus the prior quarter. Adjusted EBITDA margin was 11.4%, adjusted EBITDA amounted to €51 million (vs. €56 million a year earlier); cost‑saving measures delivered €16 million in savings. Baby care volumes remained weak, while adult and feminine hygiene showed volume growth. Net debt stood at €543 million with a leverage ratio of 2.7x. Ontex reaffirmed its full‑year guidance (adjusted EBITDA €200–210 million, free cash flow around €0, leverage ~2.5x) and expects roughly 5% sales growth in Q4 and an EBITDA improvement of more than €13 million compared with Q3. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | junio de 2026 | YoY |
|---|---|---|
| Ingresos | 854,8 M | - |
| Beneficio bruto | 232 M | - |
| Beneficio neto | -143 M | - |
| EBITDA | 78,2 M | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 118,4 M € |
Número de acciones | 80 M |
Máximo/mínimo de 52 semanas | 6,72 € - 1,31 € |
| Dividendos | No |
Beta | 0,55 |
Ratio P/E | -0,59 |
Ratio PEG | 0,01 |
Ratio P/B | 0,14 |
Ratio P/S | 0,07 |
Perfil de la empresa
Ontex Group NV ofrece soluciones de higiene personal para el cuidado infantil, femenino y de adultos en Europa Occidental, Europa Oriental, las Américas, México, el Reino Unido, Italia, Francia e internacionalmente. Ofrece productos para el cuidado infantil, como pañales y pañales-braguita, y toallitas húmedas bajo las marcas Baby Pants, Bbtips, Bio Baby, Chicolastics, Canbebe, Cremer Disney, Helen Harper, Kiddies, Little Big Change, Moltex, Pom Pom, Sapeka y Mônica; y productos para el cuidado femenino, incluidas compresas, protegeslips y tampones bajo los nombres de marca Fiore, Mia, NAT, Sincere y Silhouette. La empresa también ofrece productos de incontinencia para adultos, que comprenden pañales-braguita y pañales para adultos, toallas para incontinencia y productos de protección de camas bajo las marcas A Lovely Day, Adultmax Maturidade, Affective, Bigfral, iD, Canped, Affective, Lille Healthcare, Kylie, Serenity, Orizon y Moviment; y fabrica y vende mascarillas faciales. Vende sus productos a consumidores, minoristas y proveedores de atención sanitaria institucionales y privados, y también ofrece productos con marcas de minoristas. Ontex Group NV fue fundada en 1979 y tiene su sede en Aalst, Bélgica.
| Nombre | Ontex Group |
| CEO | Laurent Nielly |
| Sede | Aalst,
vlg Bélgica |
| Sitio web | |
| Sector | Consumo básico |
| Industria | Productos de cuidado personal |
| Salida a bolsa | 25/06/2014 |
| Empleados | 5000 |
Deep Dive
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
Euronext | ONTEX.BR |
Pnk | ONXXF |
Brussels Stock Exchange | ONTEX.BR |
Frankfurt | OT7.F |
Düsseldorf | OT7.DU |
London | 0QVQ.L |
München | OT7.MU |
Wien | ONTX.VI |